P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.
Douglas W. McMillin,Joseph Negri,Jake Delmore,Patrick Hayden,Nicholas Mitsiades,Paul G. Richardson,Nikhil C. Munshi,Robert L. Schlossman,Saveur-Michel Maira,Carlos Garcia-Echeverria,Kenneth C. Anderson,Constantine S. Mitsiades +11 more
TL;DR: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces MM cell killing at sub-μM concentrations, with significantly higher sensitivity of MM cells compared to normal tissues, suggesting that this kinase inhibitor merits further consideration for possible testing as treatment option for MM patients.
Journal ArticleDOI
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.
Sandra Wear,Paul G. Richardson,Carolyn Revta,Ravi Vij,Mark A. Fiala,Sagar Lonial,Dixil Francis,David S. Siegel,Alex Schramm,Andrzej Jakubowiak,Colleen K. Harvey,Donna E. Reece,Engin Gul,Sundar Jagannath,Lisa La,Craig C. Hofmeister,B. Jansak,Keith Stewart,Rachel Hagerty,Jeffrey L. Wolf,Beth Davis,Amrita Krishnan,Lupe Duarte,Todd M. Zimmerman,Angela Cisneros,Shaji Kumar,Ann Birgin,Robert F Ott,Leah Tasca,Susan L. Kelley,Kenneth C. Anderson,Kathy Giusti +31 more
Journal ArticleDOI
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis
Paula Rodriguez-Otero,Maria-Victoria Mateos,Albert Oriol,Alessandra Larocca,Joan Blade Creixenti,Michele Cavo,Xavier Leleu,Maxim Norkin,Omar Nadeem,John W. Hiemenz,Hani Hassoun,Cyrille Touzeau,Adrián Alegre Amor,Agne Paner,Christopher Maisel,Amitabha Mazumder,Anastasios Raptis,Noemi Puig,Marcus Thuresson,Johan Harmenberg,Olof Harlin,Paul G. Richardson +21 more
TL;DR: Melflufen plus dex showed meaningful efficacy and a safety profile characterized primarily by clinically manageable hematologic adverse events in heavily pretreated and poor-risk pts with RRMM, and was generally consistent with those of the overall population apart from more advanced International Staging System score.
Journal ArticleDOI
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK
Victoria Hamill,William Gelson,Douglas C. MacDonald,Paul G. Richardson,Stephen D. Ryder,M. Aldersley,Stuart McPherson,Sumita Verma,Rohini Sharma,Sharon J. Hutchinson,Jennifer Benselin,Eleanor Barnes,Indra Neil Guha,William L. Irving,Hamish Innes +14 more
TL;DR: In this paper , the authors investigated how surveillance is being delivered to patients with cured hepatitis C in the UK, and found that the uptake of biannual ultrasound surveillance in patients with cirrhosis is suboptimal.
Journal ArticleDOI
Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Laure Malinge,Franck Dubin,Mony Chenda Morisse,Kenneth C. Anderson +17 more
TL;DR: In this article , an anti-CD38 monoclonal antibody (Isatuximab) was used in combination with pomalidomide and dexamethasone (Pd) for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least 2 prior treatments.